undamentalytics Newsletter
Sign in

Macrogenics Inc balance sheet

At the end of fiscal 2025, Macrogenics Inc had total assets of $257m, total liabilities of $201m and shareholders' equity of $55.6m. It held $57.2m in cash against $0 of debt: net cash of $57.2m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents55481161581968421222012618112310910118357114
Receivables—22313143013231056104025
Inventory—————————041108—
Total current assets—50119165342284322269240313280222251217220322
Total assets—54126174359311374332313379335280298262257345
Accounts payable—4323424481656533
Deferred revenue (current)—2420146482211421102216156
Total current liabilities—3029272427506045517549565643109
Total debt0000000000000000
Total liabilities—62475346437589828396138146146201303
Shareholders' equity−17−8791213132692992432312962401421531165643
Net debt (negative = net cash)−55−48−116−158−196−84−212−220−126−181−123−109−101−183−57−114
Shares outstanding—4m25m28m34m35m37m42m49m56m61m62m62m63m63m64m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: IBRX vs MGNXMGNX vs NUVBBEAM vs MGNX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Macrogenics Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Macrogenics Inc.